Marginal Zone Lymphoma (MZL) Clinical Trials in Nanjing, Jiangsu
2 recruitingNanjing, Jiangsu, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07448324
Recruiting
Phase 2
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University169 enrolled1 locationNCT07208981